H
Hiroyuki Mano
Researcher at University of Tokyo
Publications - 308
Citations - 24554
Hiroyuki Mano is an academic researcher from University of Tokyo. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 66, co-authored 275 publications receiving 22190 citations. Previous affiliations of Hiroyuki Mano include Astellas Pharma & Nagasaki University.
Papers
More filters
Journal ArticleDOI
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda,Young Lim Choi,Munehiro Enomoto,Shuji Takada,Yoshihiro Yamashita,Shunpei Ishikawa,Shin-ichiro Fujiwara,Hideki Watanabe,Kentaro Kurashina,Hisashi Hatanaka,Masashi Bando,Shoji Ohno,Yuichi Ishikawa,Hiroyuki Aburatani,Toshiro Niki,Yasunori Sohara,Yukihiko Sugiyama,Hiroyuki Mano +17 more
TL;DR: It is shown that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.
Journal ArticleDOI
RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi,Manabu Soda,Yuki Togashi,Ritsuro Suzuki,Seiji Sakata,Satoko Hatano,Reimi Asaka,Wakako Hamanaka,Hironori Ninomiya,Hirofumi Uehara,Young Lim Choi,Yukitoshi Satoh,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Hiroyuki Mano,Hiroyuki Mano,Yuichi Ishikawa +17 more
TL;DR: A multivariate analysis of 1,116 adenocarcinomas containing 71 kinase-fusion–positive adenokcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathological stage and negative kinase -fusion status.
Journal ArticleDOI
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi,Manabu Soda,Yoshihiro Yamashita,Toshihide Ueno,Junpei Takashima,Takahiro Nakajima,Yasushi Yatabe,Kengo Takeuchi,Toru Hamada,Hidenori Haruta,Yuichi Ishikawa,Hideki Kimura,Tetsuya Mitsudomi,Yoshiro Tanio,Hiroyuki Mano +14 more
TL;DR: The discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor are reported.
Journal ArticleDOI
Oncogenic mutations of ALK kinase in neuroblastoma.
Yuyan Chen,Junko Takita,Young Lim Choi,Motohiro Kato,Miki Ohira,Masashi Sanada,Lili Wang,Manabu Soda,Akira Kikuchi,Takashi Igarashi,Akira Nakagawara,Yasuhide Hayashi,Hiroyuki Mano,Seishi Ogawa +13 more
TL;DR: It is demonstrated that downregulation of ALK through RNA interference suppresses proliferation of neuroblastoma cells harbouring mutated ALK, and that ALK-specific kinase inhibitors might improve its clinical outcome.
Journal ArticleDOI
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Kengo Takeuchi,Young Lim Choi,Yuki Togashi,Manabu Soda,Satoko Hatano,Kentaro Inamura,Shuji Takada,Toshihide Ueno,Yoshihiro Yamashita,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Yuichi Ishikawa,Hiroyuki Mano +13 more
TL;DR: An intercalated antibody-enhanced polymer (iAEP) method that incorporates an intercalating antibody between the primary antibody to ALK and the dextran polymer-based detection reagents should prove suitable for immunohistochemical screening of tumors positive for ALK or ALK fusion proteins among pathologic archives.